Corvus Pharmaceuticals (CRVS) Non-Current Deffered Revenue (2015 - 2018)

Corvus Pharmaceuticals' Non-Current Deffered Revenue history runs 4 years deep, the most recent figure standing at $869000.0 for Q4 2018.

• In Q4 2018, Non-Current Deffered Revenue fell 9.48% year-over-year to $869000.0; the TTM figure through Dec 2018 stood at $869000.0 (down 9.48% YoY), while the FY2018 annual figure was $869000.0, down 9.48% from the prior year.
• Non-Current Deffered Revenue for Q4 2018 stood at $869000.0, up from $627000.0 in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $1.4 million in Q4 2016, with the low at $627000.0 in Q3 2018.
• The 4-year median for Non-Current Deffered Revenue is $1.1 million (2017), against an average of $1.0 million.
• The sharpest annual moves came in 2016 and 2018: Non-Current Deffered Revenue jumped 113.4% in 2016, then sank 41.02% in 2018.
• Corvus Pharmaceuticals' Non-Current Deffered Revenue stood at $642000.0 in 2015, then jumped by 113.4% to $1.4 million in 2016, then dropped by 29.93% to $960000.0 in 2017, then dropped by 9.48% to $869000.0 in 2018.
• Business Quant data shows CRVS's Non-Current Deffered Revenue at $869000.0 in Q4 2018, $627000.0 in Q3 2018, and $738000.0 in Q2 2018.